NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Siga Technologies Inc. SIGA
17 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 94.6M
Revenue, FY2025 · full 17-year series below
Revenue $M
Net income $M
FY2025 · Revenue 94.6 · Net income 23.3
Compound annual growth
−5.1%
−5.4%
−11.8%
−16.2%
−11.4%
−14.7%
+10.1%
−2.1%
+8.6%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at −5.4% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
25 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 25.1% · Net 24.6%
ROE
FY2025 · ROE 11.2%
Each USD of equity produced 11 cents of profit this year.
The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.5 | 0.0 | 0.0 | · | · | · | · | · | · | · |
| Operating income $B | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | −0.0 | 0.4 | −0.0 | −0.0 | −0.0 | −0.2 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | −0.0 | 0.4 | −0.0 | −0.0 | −0.0 | −0.2 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.1 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 |
| Net income $B | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | −0.0 | 0.4 | −0.0 | −0.0 | −0.0 | −0.3 | −0.0 | −0.0 | 0.0 | −0.1 | −0.0 |
| Free cash flow $B | · | · | · | · | · | · | −0.0 | 0.1 | −0.0 | −0.1 | 0.0 | 0.0 | 0.1 | −0.0 | 0.0 | −0.0 | −0.0 |
| EPS, diluted $ | 0.32 | 0.82 | 0.95 | 0.46 | 0.91 | 0.71 | −0.15 | 5.18 | −0.46 | −0.69 | −0.73 | −4.97 | −0.33 | −0.27 | 0.09 | −1.12 | −0.52 |
| Dividend / sh $ | 0.60 | 0.60 | 0.45 | 0.45 | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | 185 | 72 | 47 | 97 | 0 | 0 | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | 11.2 | 28.7 | 37.1 | 19.7 | 45.7 | 49.5 | −7.2 | · | · | · | · | · | −76.0 | −40.7 | 208.9 | · | · |
| Shares out B | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 66 reconciliationsAUDITED
Reconciled in 17 of 19 fiscal years. 19 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009